^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Adstiladrin (nadofaragene firadenovec-vncg)

    i
    Company:
    FKD Therapies, Ferring, Royalty
    Drug class:
    IFNα stimulant
    Related drugs:
    Apply
    Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma (INFINITE) (NCT03710876)
    Phase 3
    Ferring Ventures Limited
    Active, not recruiting
    Last update posted :
    11/08/2024
    Initiation :
    01/21/2019
    Primary completion :
    03/29/2024
    Completion :
    04/01/2026
    MSLN • EFEMP1
    |
    gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral
    Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer (NCT01687244)
    Phase 2
    FKD Therapies Oy
    Completed
    Last update posted :
    07/24/2017
    Initiation :
    09/01/2012
    Primary completion :
    10/01/2015
    Completion :
    01/01/2016
    IFNA1
    |
    IFNA2 elevation
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) (NCT00536588)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    03/27/2015
    Initiation :
    09/01/2006
    Primary completion :
    08/01/2009
    Completion :
    08/01/2009
    IFNA1
    |
    Adstiladrin (nadofaragene firadenovec-vncg)